Gap (GAP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Strattec Security (STRT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Cambium (CMBM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

FGI Industries (FGI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Caledonia Investments Plc (CALEF) Q2 2026 Earnings Call Transcript

NIO Inc. (NYSE: NIO) reported mixed Q3 2025 results before the bell on Tuesday, beating earnings expectations while missing on revenue.

Amazon's expanding AI-driven AWS footprint contrasts with CoreWeave's rapid GPU-cloud surge, setting up a compelling matchup for growth-focused investors.

Disney and YouTube TV have settled their differences, so we have peace in our time in the media business, right? Sorry, missed it by that much.

Novo Nordisk's stock has faced pressure following its Ozempic pill's failure in Alzheimer's disease trials, introducing new downside risks for the leader in weight loss medications. While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.

LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ardent Health, Inc., (“Ardent" or the "Company") (NYSE: ARDT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Maze Therapeutics, Inc. ( MAZE ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:00 AM EST Company Participants Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma.

Looking for options to reduce your portfolio's overall tax bill? Even in an uncertain 2025, many investors will have some serious gains to pay for.

New research from CoinShares breaks down why Bitcoin and Ethereum function as complementary rather than competing assets, a distinction that could support the investment case for dual-exposure products like the CoinShares Bitcoin and Ether ETF (BTF).

Abercrombie & Fitch (ANF) came out with quarterly earnings of $2.36 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $2.5 per share a year ago.

LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Six Flags Entertainment Corporation (“Six Flags” or “the Company”) (NYSE: FUN) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the July 1, 2024 merger of legacy Six Flags Entertainment Corporation (“Legacy Six Flags”) with Cedar Fair, L.P.

Clearfield (CLFD) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.06 per share a year ago.

Inspire Medical Systems' stock recently saw a significant surge, reacting to news that appears to be important. But does the increase from yesterday indicate that this is a good time to buy, or are we merely trying to catch a falling knife?

Oscar Health stock (NYSE: OSCR) has recently increased to over $16 after reports of a possible two-year extension of Obamacare subsidies, which may positively influence demand for health insurance via the Affordable Care Act (ACA) Marketplace. This surge signifies investor confidence regarding imminent policy support, yet the central question persists: Is OSCR stock still an enticing purchase following its recent increase?

The housing market is still in rough shape, impacting performance for all companies in the sector—from homebuilders to home improvement companies. However, it may be on track for a recovery, as easing interest rates and home prices have triggered a slow trickle of improvement that is expected to strengthen in 2026.